These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 10801168)

  • 1. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.
    Cox T; Lachmann R; Hollak C; Aerts J; van Weely S; Hrebícek M; Platt F; Butters T; Dwek R; Moyses C; Gow I; Elstein D; Zimran A
    Lancet; 2000 Apr; 355(9214):1481-5. PubMed ID: 10801168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
    Pastores GM; Barnett NL; Kolodny EH
    Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.
    Elstein D; Hollak C; Aerts JM; van Weely S; Maas M; Cox TM; Lachmann RH; Hrebicek M; Platt FM; Butters TD; Dwek RA; Zimran A
    J Inherit Metab Dis; 2004; 27(6):757-66. PubMed ID: 15505381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Gaucher's disease with OGT 918.
    Mistry PK
    Lancet; 2000 Aug; 356(9230):676-7. PubMed ID: 10968454
    [No Abstract]   [Full Text] [Related]  

  • 5. Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease.
    Giraldo P; Latre P; Alfonso P; Acedo A; Alonso D; Barez A; Corrales A; Franco R; Roldan V; Serrano S; Pocovi M
    Haematologica; 2006 May; 91(5):703-6. PubMed ID: 16627252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Gaucher's disease with OGT 918.
    Kranda M
    Lancet; 2000 Aug; 356(9230):677. PubMed ID: 10968455
    [No Abstract]   [Full Text] [Related]  

  • 7. Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease.
    Moyses C
    Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):955-60. PubMed ID: 12803929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease.
    Heitner R; Elstein D; Aerts J; Weely Sv; Zimran A
    Blood Cells Mol Dis; 2002; 28(2):127-33. PubMed ID: 12064906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders.
    Lachmann RH
    Drugs Today (Barc); 2006 Jan; 42(1):29-38. PubMed ID: 16511609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.
    Cox TM; Drelichman G; Cravo R; Balwani M; Burrow TA; Martins AM; Lukina E; Rosenbloom B; Ross L; Angell J; Puga AC
    Lancet; 2015 Jun; 385(9985):2355-62. PubMed ID: 25819691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective treatment of an elderly patient with Gaucher's disease and Parkinsonism: a case report of 24 months' oral substrate reduction therapy with miglustat.
    Hughes DA; Ginsberg L; Baker R; Goodwin S; Milligan A; Richfield L; Mehta AB
    Parkinsonism Relat Disord; 2007 Aug; 13(6):365-8. PubMed ID: 17049454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Miglustat.
    McCormack PL; Goa KL
    Drugs; 2003; 63(22):2427-34; discussion 2435-6. PubMed ID: 14609352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Miglustat: new drug. In type 1 Gaucher's disease : a slight benefit after imiglucerase therapy.
    Prescrire Int; 2005 Oct; 14(79):168-70. PubMed ID: 16285070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gaucher disease and the clinical experience with substrate reduction therapy.
    Zimran A; Elstein D
    Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):961-6. PubMed ID: 12803930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
    Pastores GM; Elstein D; Hrebícek M; Zimran A
    Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
    Giuffrida G; Lombardo R; Di Francesco E; Parrinello L; Di Raimondo F; Fiumara A
    J Med Case Rep; 2016 Nov; 10(1):315. PubMed ID: 27821156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A less costly regimen of alglucerase to treat Gaucher's disease.
    Figueroa ML; Rosenbloom BE; Kay AC; Garver P; Thurston DW; Koziol JA; Gelbart T; Beutler E
    N Engl J Med; 1992 Dec; 327(23):1632-6. PubMed ID: 1435900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, controlled trial of miglustat in Gaucher's disease type 3.
    Schiffmann R; Fitzgibbon EJ; Harris C; DeVile C; Davies EH; Abel L; van Schaik IN; Benko W; Timmons M; Ries M; Vellodi A
    Ann Neurol; 2008 Nov; 64(5):514-22. PubMed ID: 19067373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gaucher's disease in Lithuania: its diagnosis and treatment.
    Kleinotienė G; Tylki-Szymanska A; Czartoryska B
    Medicina (Kaunas); 2011; 47(7):405-11. PubMed ID: 22112991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alglucerase. A review of its therapeutic use in Gaucher's disease.
    Whittington R; Goa KL
    Drugs; 1992 Jul; 44(1):72-93. PubMed ID: 1379912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.